View Clinical Trial (Medical Research Study)
Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10065 |
| Conditions: |
|
Cancer |
| Purpose: |
|
The purpose of this study is to develop blood tests and urine tests that can tell doctors
how much radiation a person has been exposed to. Doctors know how much radiation patients
are exposed to in certain medical situations. An example of this would be radiation
treatment for cancer. Radiation treatment machines are programmed to give exact doses of
radiation.
|
| Study Summary: |
|
MSKCC patients undergoing TBI as part of a hematopoietic stem cell transplant (HSCT) will
have blood drawn and urine collected for use in the validation and refinement of new methods
for rapid high-throughput radiation biodosimetry. These blood and urine samples will be
collected before, and at defined times after TBI. Blood sampling will occur in the same
manner that it does during routine patient care during HSCT.
|
| Criteria: |
|
Inclusion Criteria:
- Patients greater than 4 years of age at Memorial Sloan-Kettering Cancer Center
- Must be undergoing hematopoietic stem cell transplantation (either autologous or
allogenic) in conjunction with a conditioning regimen that includes TBI (single or
multiple fraction)
- Functional central venous catheter
Exclusion Criteria:
- No subjects will be excluded from the proposed research study for demographic
reasons. Treatment with growth factors, such as keratinocyte growth factor (KGF),
will not be grounds for exclusion.
- Subjects who will receive radiation therapy within 5 days prior to TBI will be
excluded.
- Subjects who will receive systemic antineoplastic chemotherapy within 7 days prior to
TBI not have research bloods collected. Only urine will be collected from these
patients.
- Subjects less than 4 years of age will be excluded because they are not treated with
TBI.
- Based on current knowledge, we will not a priori exclude patients based on disease
status (ie, patients in or out of remission will be included in this study), type of
disease(ie, chromosomal breakage syndromes), or previous therapies (unless exclusion
criteria is met).
|
| NCT ID: |
|
NCT00581958 |
| Primary Contact: |
|
Principal Investigator
Christopher Barker, MD
Memorial Sloan-Kettering Cancer Center
Christopher A. Barker, MD
Phone: 212-639-8168
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New York, New York 10065
United States
Christopher Barker, MD
Phone: 212-639-8168
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|